Case report

Pituicytoma: A rare case report of sellar and suprasellar tumor

Chia-Fang Shen *, Szu-Yuan Liu, Chung-Hsin Lee, Szu-Yen Pan, Chiung-Chyi Shen

Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung City 40705, Taiwan

A R T I C L E  I N F O

Keywords:
Pituicytoma
Pituitary tumors
Thyroid transcription factor 1 (TTF-1)
Case report

A B S T R A C T

Introduction: Pituicytomas are low-grade glial tumors in the sellar and suprasellar region. They may be easily confused with pituitary lesions. We review the literature in order to better understand and categorize the natural history, clinical presentations, and treatments.

Presentation of case: A 45-year-old female patient who complained of left eye blurred vision for 2 months. The imaging study revealed a solid sellar tumor with marked homogeneous enhancement following intravenous administration of gadolinium, and compression of the optic chiasm. Thus, under the preoperative diagnosis of pituitary macroadenoma, the patient underwent endoscope-assisted surgery via the transphenoidal approach. The patient recovered well after surgery. The histopathological diagnosis was pituicytoma, WHO grade I.

Clinical discussion: Pituicytomas are defined as a circumscribed low-grade glial tumor arising from the neurohypophysis or infundibulum with bipolar spindle cells arranged in a fascicular or storiform pattern (a cartwheel). The clinical symptoms are variable depending on the tumor size and location. They usually present due to mass effect. The radiographic characteristics are not nonspecific. The diagnosis of pituicytoma is based on histopathological evidence. Pituicytomas consist of a solid proliferation of elongated spindle cells arranged in interlacing fascicles and/or in a “storiform” pattern. In immunohistochemical studies, pituicytomas was strongly expressed in TTF-1.

Conclusion: Pituicytomas are benign, slow-growing glial tumors. It is difficult to diagnosed before operation as its clinical presentations and imaging studies resemble those of non-functional pituitary adenomas. The best chance of successful treatment is gross total resection by the endoscopic approach or transcranial approach.

1. Introduction and importance

Pituicytomas are rare circumscribed low-grade glial tumors arising from the neurohypophysis or infundibulum. The tumor is slow growing and benign, and histologically corresponds to World Health Organization (WHO) grade I [1,2]. They may be easily confused with pituitary lesions, including pituitary adenoma, craniopharyngiomas, and so on, due to their location in the sellar and suprasellar region. In this study, we review the literature in order to better understand and categorize the natural history, clinical presentation, and treatments. This case report has been reported in line with the SCARE 2020 criteria [3].

2. Case presentation

A 45-year-old female patient who complained of left eye blurred vision over the left side field for 2 months. Progressive left eye blurred vision with intermittent headache and photophobia was noted over 2 weeks prior to admission.

No visual field defect was observed by neurological examination. Visual evoked potential (VEP) was normal. Endocrine studies for the pituitary gland were normal except for a mildly elevated level of serum prolactin (PRL) (61.29 ng/mL). The Brain Magnetic Resonance Imaging (MRI) study disclosed a solid sellar tumor with marked homogeneous enhancement following intravenous administration of gadolinium, and compression of the optic chiasm was noted. The tumor was isointense on T1-weighted images and hyperintense on T2-weighted images [Fig. 1]. Thus, under the preoperative diagnosis of pituitary macroadenoma with optic neuropathy, the patient underwent endoscope-assisted surgery via the transsphenoidal approach.

Gross total resection of the mass was performed by our surgeon. It bled easily during the operation, but hemostasis was successfully achieved using FLOSEAL hemostatic matrix and bipolar coagulator. An intraoperative view revealed a yellowish soft tumor with slight sella floor erosion.

* Corresponding author.

E-mail addresses: jenny150142@gmail.com (C.-F. Shen), syliu@vghtc.gov.tw (S.-Y. Liu), zacklee228@gmail.com (C.-H. Lee), psyen@vghtc.gov.tw (S.-Y. Pan), ccschen@vghtc.gov.tw (C.-C. Shen).

https://doi.org/10.1016/j.ijscr.2022.107553
Received 7 May 2022; Received in revised form 21 August 2022; Accepted 22 August 2022
Available online 26 August 2022
2210-2612/© 2022 The Authors. Published by Elsevier Ltd on behalf of LJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The patient recovered well after surgery. The symptom of blurred vision was much improved. In addition, no CSF leakage or transient diabetes insipidus were found. Hormone levels were within the normal ranges after operation. Postoperative visual field was examined and it was almost normal [Fig. 2].

The follow-up MRI at 1 year later after operation showed grossly total resection without evidence of residual tumor or tumor recurrence [Fig. 1].

Pathological examination revealed fragmented of normal pituitary gland and tumor composed of mixed round to spindle, amphophilic cells, and round, eosinophilic granular cells. The tumor was close to the respiratory tract epithelium with entrapped submucosal glands. Marked

Fig. 1. Brain MRI.
lymphoplasmacytic infiltration was observed. The vasculature was also easily seen, with focal staghorn-like appearance. No tumor necrosis was found. Immunohistochemical (IHC) studies were positive for epithelial membrane antigen (EMA), S-100 protein, and diffuse strong positive staining for thyroid transcription factor 1 (TTF-1) and focal weak positive staining for CD99 were found. However, results were negative for cytokeratin (CK) AE1/AE3, CAM5.2, glial fibrillary acidic protein (GFAP), CD34, and signal transducer and activator of transcription 6 (STAT6). The histopathological diagnosis was pituicytoma, WHO grade I. Histopathologic features are shown in Fig. 3.

3. Clinical discussion

Pituicytomas are defined as a circumscribed low-grade glial tumor arising from the neurohypophysis or infundibulum with bipolar spindle cells arranged in a fascicular or storiform pattern (a cartwheel). The tumor is slow growing and benign, and histologically corresponds to World Health Organization (WHO) grade I [2,4]. It occurs in adults with a slight predominance in males.

3.1. Clinical presentation

The clinical symptoms are variable depending on the tumor size and location. They usually present due to mass effect, such as visual acuity or visual field defects, which are caused by compression of the optic nerves and/or optic chiasm. Pituitary stalk compression results in panhypopituitarism or hyperprolactinemia. The patients may also complain of headache, dizziness, and fatigue. Rarely, the tumor may present with sudden onset of symptoms due to spontaneous hemorrhage [5].

3.2. Imaging findings

Pituicytomas are solid intra- or suprasellar tumors that tend to be well circumscribed with homogeneous appearance on computed tomography (CT) or magnetic resonance imaging (MRI) scans. Sometimes, they can exhibit sellar enlargement and bony remodeling. These findings are similar to those of pituitary adenoma.

On the MRI scans, pituicytomas commonly appeared hypointense to isointense on T1-weighted images and hyperintense on T2-weighted images with marked homogenous enhancement after administration of gadolinium [1,6–9]. This presentation demonstrates a highly vascular tumor. Therefore, the radiological differential diagnosis should include other sellar or suprasellar tumors including meningioma, craniohypophysial adenoma, hemangiopericytoma, granular cell tumor, and pilocytic astrocytoma. The rapidity of enhancement correlates with increased vascularity of these lesions, according to Gibbs et al. [10]. They reported the presence of a significant vascular blush of these tumors on selected internal carotid artery angiograms. Thus, we can speculate that for pituicytoma, there may be a slightly delayed enhancement on dynamic contrast-enhanced studies, unlike pituitary adenoma, which is apparently enhanced during the earlier arterial phase. In addition, the angiogram revealed prominent arterial feeding from the superior hypophyseal arteries, which supply both the diaphragm sellae and the pituitary stalk, and the appearance of a thickened stalk suggests the tumor is of infundibular origin. Distinguishing this vascular pattern from meningioma can be problematic, but the absence of external carotid artery dural feeders favors pituicytoma [10,11].

The radiographic preoperative characteristics of pituicytomas are not nonspecific, and it is often difficult to identify these tumors before operation, especially for nonfunctioning pituitary adenoma in our case. The distinctive diagnosis of pituicytoma is depended on histologic appearance and immunohistochemical findings.

3.3. Histopathology

The diagnosis of pituicytoma is based on histopathological evidence. In the 2016 WHO classification of CNS tumors, pituicytoma was defined as a low-grade glial tumors found in the posterior pituitary and infundibulum, presumably arising from pituicytes. Pituicytomas consist of a solid proliferation of elongated spindle cells arranged in interlacing fascicles and/or in a “storiform” pattern [1].

The tumor cells have an abundant eosinophilic cytoplasm and a rich capillary network. Tumor cell nuclei are round to oval, with rare to absent evidence of atypia or mitotic figures. There are no Rosenthal fibers or eosinophilic granular bodies, which usually helps to distinguish between pituicytomas and pilocytic astrocytomas [12]. Also, there is a lack of Antoni A and B pattern, psammoma bodies, which could help to distinguish pituicytomas from schwannomas and meningiomas.

In immunohistochemical studies, pituicytomas were strongly expressed in TTF-1 and show negative or low/moderately positive staining for GFAP. Pituicytes are considered to be modified neuroglial cells and show positive immunohistochemical staining for GFAP and TTF-1. TTF-1 is strongly expressed in fetal and adult human pituicytes. It is specifically expressed in pituicytomas, granular cell tumors, and spindle cell oncocytomas. Thus, it is useful for distinguishing pituicytomas from other sellar tumors [13]. In addition, pituicytomas demonstrated positive immunofluorescence staining for S-100, vimentin protein. Other markers, including EMA, SSTR2A, and synaptophysin, revealed variable staining in the literature [Table 1] [1,7,14,15].

Fig. 2. Postoperative visual field. A: Oculus Sinister (O.S), B: Oculus Dexter (O.D).
3.4. Treatments

Complete resection of the tumor is the main treatment for pituicytoma. The role of adjuvant radiotherapy and chemotherapy is unclear now and needs further study for it. The local recurrence rate is usually low and no malignant transformation or cerebrospinal dissemination has been reported. The choice of surgical route used may depended on the tumor size, whether invasion to other structures has occurred, and the technique of the surgeon. The craniotomy transcral approach, endoscope-assisted transsphenoidal approach, or even extended endoscope-assisted transsphenoidal approach with skull base reconstruction showed difference in the rate of tumor recurrence and postoperative complications such as infection, vessels or nerve injury. Thus, the surgical resection should be also considered about functional preservation. Postoperative radiotherapy should be recommended in patients where gross total resection is not feasible. And an MRI for closely following up after operation is essential, even for those patients undergoing complete tumor resection.

Given the benign and slow-growing characteristics of pituicytomas, asymptomatic patients may choose a wait-and watch approach. When

---

**Fig. 3.** Histopathologic features of pituicytoma. (a, b, c) Tumors were composed of mixed round to spindle, amphophilic cells and round, eosinophilic granular cells. (a) 500 μm (b) 100 μm (c) 50 μm. Immunohistochemical (IHC) studies: Negative for (d) Cytokeratin (CK), (e) Glial fibrillary acidic protein (GFAP), (f) CD34, (g) Signal transducer and activator of transcription 6 (STAT6). (h) CAM5.2. Positive for (i, j) Thyroid transcription factor 1 (TTF-1): diffuse strong, (k) S-100 protein (l) epithelial membrane antigen (EMA), (m) CD99, focal weak.
Fig. 3. (continued).
the tumor recurs or progresses, it is recommended to re-operate and remove the lesion completely as far as possible [16,17].

4. Conclusion

Pituicytomas are benign, slow-growing glial tumors that arise from the neurohypophysis or infundibulum. It is difficult to diagnosed before operation as its clinical presentations and imaging studies resemble those of non-functional pituitary adenomas. The best chance of successful treatment is gross total resection by the endoscopic approach or transcranial approach.

Sources of funding

This research did not receive any funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

Not applicable.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

CF Shen, resident, first author, writing the paper, literature review. SY Liu, surgeon, background research, edit the manuscript. CH Lee, surgeon, background research, edit the manuscript. SY Pan, background research, literature review. CC Shen, supervision.

Research registration

Not applicable.

Guarantor

Chiung-Chyi Shen – Chief of Neurological Institute, Head of Department of Neurosurgery, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Section 4, Taichung, Taiwan 407, ROC.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

All authors declare that they have no competing interests.

References

[1] D.J. Brat, B.W. Scheithauer, S.M. Stausgaitis, R.N. Holtzman, S. Morgello, P.C. Burger, Pituicytoma: a distinctive low-grade glioma of the neurohypophysis, Am. J. Surg. Pathol. 24 (2000) 362-368.

[2] D.J. Brat, B.W. Scheithauer, G.N. Fuller, T. Tihan, Newly codified glial neoplasms of the 2007 WHO classification of tumours of the central nervous system: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma, Brain Pathol. 17 (2007) 319-324.

[3] R.A. Agba, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, SCARE group. The SCARE 2020 guideline: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020), 226-23.

[4] D.N. Louis, H. Ohgaki, O.D. Wiestler, et al., WHO classification of tumours of the central nervous system, Acta Neuropathol. 131 (2016) 863-820.

[5] R.J. Beveniste, D. Purshiet, H. Byun, Pituicytoma presenting with spontaneous hemorrhage, Pituitary 9 (2006) 53-58.

[6] B. Shah, M.H. Lipper, E.R. Laws, M.J. Spellman, Posterior pituitary astrocytoma: a rare tumor of the neurohypophysis: a case report, Am. J. Neuroradiol. 26 (2005) 1858-1861.

[7] D. Figarella-Branger, H. Dufour, C. Fernandez, C. Bouvier-Labit, F. Grisoli, J.F. Pellissier, Pituicytomas, a mis-diagnosed benign tumor of the neurohypophysis: report of three cases, Acta Neuropathol. 104 (2002) 313-319.

[8] T.R. Hurley, C.M. D’Angelo, R.A. Claussen, S.B. Wilkinson, R.D. Pasavoy, Magnetic resonance imaging and pathological analysis of a pituicytoma: case report, Neurosurgery 35 (1994) 314-317.

[9] T. Katsuta, T. Inoue, H. Nakagaki, M. Takeshita, K. Morimoto, T. Iwaki, Distinctions between pituicytoma and ordinary pitocytic astrocytoma. Case report, J. Neurosurg. 98 (2003) 404-406.

[10] W.N. Gibbs, E.S. Monuki, M.E. Linskey, A.N. Hasso, Pituicytoma: diagnostic features on selective carotid angiography and MR imaging, Am. J. Neuroradiol. 27 (2006) 1639-1642.

[11] Francesca Secchi, Paolo Merciadri, Diego Criminnelli Rossi, Alessandro D’Andrea, Gianluigi Zona, Pituicytomas: radiological findings, clinical behavior and surgical management, Acta Neurochir. 154 (2012) 649-657.

[12] Y. Nakasu, S. Nakasu, A. Saito, S. Horiguchi, T. Kameya, Pituicytoma. Two case reports, Neurol. Med. Chir. (Tokyo) 46 (2006) 152-156.

[13] E.B. Lee, T. Tihan, B.W. Scheithauer, P.J. Zhang, N.K. Gonatas, Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J. Neuroenaphol. Exp. Neurol. 68 (2009) 482-488.

[14] C. Hagel, R. Buslei, M. Buchfelder, R. Fahlbusch, M. Bergmann, A. Giese, J. Flitsch, D.K. Lüdecke, M. Glatzel, W. Saeger, Immunoprofiling of glial tumours of the neurohypophysis suggests a common pituicytic origin of neoplastic cells, Brain Pathol. 20 (2) (2010) 211-217.

[15] O. Mete, M.B. Lopes, S.L. Asa, Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma, Am. J. Surg. Pathol. 37 (2014) 1694-1699.

[16] Xiaoyu Yang, Xiaoliang Liu, Wensen Li, Dawei Chen, Pituicytoma: a report of three cases and literature review, Oncol. Lett. 12 (5) (2016) 3417–3422.

[17] Liu-Dong Wei, Chao Li, Da. Li, Xing-Ju Liu, Run-Ting Li, Lian-Wang Li, Jun-Mei Wang, Da-Biao Zhou, Treatment and prognostic factors of pituicytoma: a single-center experience and comprehensive literature review, Pituitary 24 (2021) 754-767.